Evidence map›Paper›PMID 33837736›Full record

ArticleThe Journal of biological chemistry

A general chemical crosslinking strategy for structural analyses of weakly interacting proteins applied to preTCR-pMHC complexes.

Réka Mizsei, Xiaolong Li, Wan-Na Chen, Monika Szabo, Jia-Huai Wang, Gerhard Wagner, Ellis L Reinherz, Robert J Mallis

Open access · goldAbstract read
In one paragraph

Article in The Journal of biological chemistry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 3 countries.

Réka MizseiLaboratory of Immunobiology, Dana Farber Cancer Institute, Boston, Massachusetts, USA; Department of Biochemistry, Semmelweis University, Budapest, Hungary.
Xiaolong LiLaboratory of Immunobiology, Dana Farber Cancer Institute, Boston, Massachusetts, USA; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA.
Wan-Na ChenDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.
Monika SzaboMonash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC, Australia.
Jia-Huai WangLaboratory of Immunobiology, Dana Farber Cancer Institute, Boston, Massachusetts, USA; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA; Department of Cancer Biology, Dana Farber Cancer Institute, Boston, Massachusetts, USA; Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, USA.
Gerhard WagnerDepartment of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA.
Ellis L ReinherzLaboratory of Immunobiology, Dana Farber Cancer Institute, Boston, Massachusetts, USA; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA; Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: ellis_reinherz@dfci.harvard.edu.
Robert J MallisLaboratory of Immunobiology, Dana Farber Cancer Institute, Boston, Massachusetts, USA; Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, USA; Department of Dermatology, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: robert_mallis@hms.harvard.edu.
Harvard University · USMonash University · AUSemmelweis University · HU

Funding

Protein Production CoreP01AI143565 · NIAID · DANA-FARBER CANCER INST · PI ELLIS L REINHERZ · 2020 to 2026
$19.9M
STRUCTURE BASIS OF IMMUNE-CELL SURFACE RECEPTOR FUNCTIONR01AI037581 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WAGNER, GERHARD · 1996 to 2021
$6.7M
CONTROL AND ACTIVATION OF THE TUMOR NECROSIS FACTOR RECEPTORSR01AI150709 · NIAID · HARVARD MEDICAL SCHOOL · PI WAGNER, GERHARD, WU, HAO · 2020 to 2024
$4.0M
TR&D 4 -- Advanced Magic Angle Spinning NMR methodsP41GM132079 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI GRIFFIN, ROBERT GUY · 2019 to 2021
$3.6M
Next Generation Solution NMR Techniques for GPCR Structure, Dynamics and FunctionR01GM129026 · NIGMS · HARVARD MEDICAL SCHOOL · PI WAGNER, GERHARD · 2018 to 2021
$2.0M
Thymocyte integrin regulation by plexinD1R01AI115698 · NIAID · DANA-FARBER CANCER INST · PI REINHERZ, ELLIS L · 2015 to 2018
$1.7M
600 MHz NMR Spectrometer ConsoleS10OD028526 · OD · HARVARD MEDICAL SCHOOL · PI WAGNER, GERHARD · 2020 to 2020
$649k
NIAID NIH HHS P01 AI143565NIAID NIH HHS R01 AI037581NIAID NIH HHS R01 AI115698NIAID NIH HHS R01 AI150709NIGMS NIH HHS P41 GM132079NIGMS NIH HHS R01 GM129026NIH HHS S10 OD028526
6 · The paper itself

Abstract

T lymphocytes discriminate between healthy and infected or cancerous cells via T-cell receptor-mediated recognition of peptides bound and presented by cell-surface-expressed major histocompatibility complex molecules (MHCs). Pre-T-cell receptors (preTCRs) on thymocytes foster development of αβT lymphocytes through their β chain interaction with MHC displaying self-peptides on thymic epithelia. The specific binding of a preTCR with a peptide-MHC complex (pMHC) has been identified previously as forming a weak affinity complex with a distinct interface from that of mature αβTCR. However, a lack of appropriate tools has limited prior efforts to investigate this unique interface. Here we designed a small-scale linkage screening protocol using bismaleimide linkers for determining residue-specific distance constraints between transiently interacting protein pairs in solution. Employing linkage distance restraint-guided molecular modeling, we report the oriented solution docking geometry of a preTCRβ-pMHC interaction. The linkage model of preTCRβ-pMHC complex was independently verified with paramagnetic pseudocontact chemical shift (PCS) NMR of the unlinked protein mixtures. Using linkage screens, we show that the preTCR binds with differing affinities to peptides presented by MHC in solution. Moreover, the C-terminal peptide segment is a key determinant in preTCR-pMHC recognition. We also describe the process for future large-scale production and purification of the linked constructs for NMR, X-ray crystallography, and single-molecule electron microscopy studies.

Indexed as

Antigens, SurfaceHumansMajor Histocompatibility ComplexMembrane GlycoproteinsNuclear Magnetic Resonance, BiomolecularPeptidesProtein BindingProtein Interaction Domains and MotifsReceptors, Antigen, T-CellReceptors, Antigen, T-Cell, alpha-betaThymocytesT-LymphocytesAntigens, SurfaceMembrane GlycoproteinsPeptidespre-T cell receptor alphaReceptors, Antigen, T-CellReceptors, Antigen, T-Cell, alpha-betahomobifunctional crosslinkingimmunologymolecular modelingnuclear magnetic resonance (NMR)peptide–major histocompatibility complex molecule (pMHC)pre-T cell receptor (preTCR)protein–protein interactionpseudocontact shift (PCS) NMRT-cell receptor (TCR)thymocyte development

Identifiers

PMID33837736
PMCPMC7948749
OpenAlexW3118857201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.